Grupo Ferrer Internacional, S.A.
https://www.ferrer.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Grupo Ferrer Internacional, S.A.
Pfizer Gets AAV Capsid Rights From Voyager For Gene Therapy R&D
Deal Snapshot: Pfizer has 12 months to evaluate a pair of AAV capsids from Voyager’s TRACER platform for use as delivery mechanisms in gene therapy candidates for neurologic and CV indications.
Tech Transfer Roundup: Mydecine, Johns Hopkins Pair Up To Study Psychedelics
BioMed X teams with J&J on inflammation, drug delivery research. Stem cell firm Calidi inks licensing deals with U. of Chicago, City of Hope and Northwestern. MD Anderson teams with Blueprint and Hummingbird.
Adverum Halts Phase II Gene Therapy Trial After Patient’s Vision Loss
Slated to begin a Phase III later this year of ADVM-022 in wet AMD, Adverum had to scuttle a Phase II study of the gene therapy in DME after a patient suffered ocular hypotension, panuveitis and vision loss in the treated eye.
Relief For UniQure Hemophilia Program Sends Ball To FTC’s Court
While anticipated, the removal of the hold on uniQure’s hemophilia B program removes significant overhang, as the focus shifts to an anticipated FTC antitrust clearance of its CSL Behring deal.
Company Information
- Industry
- Biotechnology
- In Vitro Diagnostics
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Generic Drugs
- Nutraceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
- Other Names / Subsidiaries
-
- Addicere Therapeutics, Inc.
- Alexza Pharmaceuticals, Inc.